Ligand id: 9602

Name: betrixaban

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 107.41
Molecular weight 451.14
XLogP 4.96
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Betrixaban was FDA approved in June 2017 for extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE), in hospitalized patients at risk for thromboembolic complications.
Mechanism Of Action and Pharmacodynamic Effects
Serine protease factor Xa catalyzes the conversion of prothrombin to thrombin, the final enzyme responsible for fibrin clot formation in the blood coagulation cascade. Direct inhibition of factor Xa has anti-thrombotic action, and small molecule factor Xa inhibitors are used clinically.